Novartis class 1 new drug Sinimod approved in China

On May 11, the State Food and Drug Administration issued an announcement to approve the listing of the first class of innovative drug Sinimod tablets (trade name: Wan Li Neng) declared by Novartis Pharma AG through the priority review and approval process for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease.

On May 11, the State Food and Drug Administration issued an announcement to approve the listing of the first class of innovative drug Sinimod tablets (trade name: Wan Li Neng) declared by Novartis Pharma AG through the priority review and approval process for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease.

Data from Menet.com shows that the product’s global sales in 2019 will be US $ 26 million.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/12/novartis-class-1-new-drug-sinimod-approved-in-china/.

Leave a Reply

Please Login to Comment